Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Change in Cash (2016 - 2025)

Historic Change in Cash for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to -$2.7 million.

  • Cytosorbents' Change in Cash rose 389.05% to -$2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 million, marking a year-over-year decrease of 24659.82%. This contributed to the annual value of -$5.9 million for FY2024, which is 2879.08% up from last year.
  • As of Q3 2025, Cytosorbents' Change in Cash stood at -$2.7 million, which was up 389.05% from -$1.4 million recorded in Q2 2025.
  • Over the past 5 years, Cytosorbents' Change in Cash peaked at $5.6 million during Q4 2023, and registered a low of -$12.9 million during Q2 2022.
  • Over the past 5 years, Cytosorbents' median Change in Cash value was -$3.0 million (recorded in 2021), while the average stood at -$3.3 million.
  • Per our database at Business Quant, Cytosorbents' Change in Cash tumbled by 34973.17% in 2022 and then skyrocketed by 146594.84% in 2023.
  • Quarter analysis of 5 years shows Cytosorbents' Change in Cash stood at -$7.2 million in 2021, then soared by 94.35% to -$407672.0 in 2022, then skyrocketed by 1465.95% to $5.6 million in 2023, then crashed by 143.17% to -$2.4 million in 2024, then decreased by 10.97% to -$2.7 million in 2025.
  • Its Change in Cash was -$2.7 million in Q3 2025, compared to -$1.4 million in Q2 2025 and $3.3 million in Q1 2025.